These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39380740)

  • 21. Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zhao ZX; Yang TY; Wang YH; Zhang L; Li J; Su YW
    Br J Clin Pharmacol; 2024 Sep; 90(9):2166-2179. PubMed ID: 38831641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database.
    Fu Z; Liu J; Zhang C; Hu H; Li S; Zhang Y; You R
    Front Pharmacol; 2024; 15():1383212. PubMed ID: 38948476
    [No Abstract]   [Full Text] [Related]  

  • 24. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events.
    Kinoshita S; Hosomi K; Yokoyama S; Takada M
    Int J Med Sci; 2020; 17(3):302-309. PubMed ID: 32132864
    [No Abstract]   [Full Text] [Related]  

  • 25. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Zhou C; Peng S; Lin A; Jiang A; Peng Y; Gu T; Liu Z; Cheng Q; Zhang J; Luo P
    EClinicalMedicine; 2023 May; 59():101967. PubMed ID: 37131541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
    Allouchery M; Beuvon C; Pérault-Pochat MC; Roblot P; Puyade M; Martin M
    Clin Pharmacol Ther; 2022 Jul; 112(1):164-170. PubMed ID: 35426120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Fusaroli M; Giunchi V; Repaci A; Pelusi C; Mollica V; Massari F; Ardizzoni A; Poluzzi E; Pagotto U; Di Dalmazi G
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230533
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
    Ren X; Wang H; Deng L; Wang W; Wang Y
    Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
    Raschi E; Fusaroli M; Ardizzoni A; Poluzzi E; De Ponti F
    Breast Cancer Res Treat; 2021 Feb; 186(1):219-227. PubMed ID: 33150548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
    Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
    Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
    Liu Y; Chen Y; Zeng Z; Liu A
    Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
    Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
    J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database.
    Liu G; Zhang S; Mo Z; Huang T; Yu Q; Lu X; He P
    Front Pharmacol; 2024; 15():1407894. PubMed ID: 38953101
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS).
    He S; Chen B; Li C
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):59. PubMed ID: 39215339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments.
    Nawa H; Niimura T; Yagi K; Goda M; Zamami Y; Ishizawa K
    Cancer Rep (Hoboken); 2022 Jan; 5(1):e1402. PubMed ID: 33939324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
    Rana P; Aleo MD; Wen X; Kogut S
    Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.